Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

by Jiaqi Han MD, Desheng Xiao PhD, Chongqing Tan PhD, Xiaohui Zeng MD, Huabin Hu MD, Shan Zeng PhD, MD, Qin Jiang MD, Longjiang She MD, Linli Yao MD, Li Li MD, Lanhua Tang PhD, Jian Ma PhD, MD, Jin Huang PhD, MD, Liangfang Shen PhD, MD
Published 2020-02-01